Skip to main content
. Author manuscript; available in PMC: 2011 Dec 15.
Published in final edited form as: Pediatr Blood Cancer. 2010 Aug 13;55(7):1323–1328. doi: 10.1002/pbc.22609

Table V. Ispinesib plasma pharmacokinetic parameters by dose level.

Dose level mg/m2/dose Patient Cmax
(ng/mL)
AUClast
(hr*ng/mL)
AUCINF
(hr*ng/mL)
t1/2
(hr)
Clearance
(L/hr/m2)
Vss
(L/m2)
5 737478** 86 945 1662 44 3.0 177 *
757897 145 908 938 9 5.3 61


7 744676 181 1319 1449 14 4.8 84 *
758892** 244 3716 5733 32 1.2 51
767535 1900 4090 4596 18 1.5 24 *
769075 75 851 970 15 7.2 145


9 763246 1880 4814 5243 16 1.7 23 *
763770 281 2506 3811 33 2.4 102
769877 149 1526 1865 19 4.8 118


12 764399 149 819 890 13 13.5 193
771172** 204 732 1690 8 7.1 83
*

Protocol deviation with samples obtained from same venous access site as drug administration; concentrations obtained may be overestimates;

*

AUC extrapolated values for these patients were >30% (fewer data points were available for these patients).